Home/PK MED/Vincent Dagommer

VD

Vincent Dagommer

Chief Financial Officer

Therapeutic Areas

Rheumatology Hematology Musculoskeletal Disorders

PK MED Pipeline

Drug	Indication	Phase
PKM-01	Gout Flare	Phase 2
PKM-011	Osteoarthritis	Pre-clinical
PKM-02	Hemoglobinopathies (e.g., via HSCT enhancement)	Pre-clinical

Leadership Team at PK MED

Gauthier Pouliquen, PhD

Chief Executive Officer

Charles Sanson, PhD

Head of Research & Development

Farah Marzouki, Eng., MSc

Head of Pharmaceutical Development

Julien Grassot, PhD

Head of Biostatistics and Clinical Development

Dr. Philippe Pouletty

Chairman of the Board

View full PK MED profile